2008
Life Sciences
Biotechnology
Phase 1 – Safety & dosing Trial for Pancreatic Cancer Therapy
Virginia Biosciences Commercialization Center (VBCC)
Richmond (Virginia)
BioCancell Therapeutics Ltd.
Jerusalem (Jerusalem Region)
Project description
BioCancell teamed with Virginia Bioscience Commercialization Center (VBCC) to conduct Phase I & II clinical trials of its lead drug-candidate,…
Read More
BioCancell teamed with Virginia Bioscience Commercialization Center (VBCC) to conduct Phase I & II clinical trials of its lead drug-candidate, BC-819 as a treatment for pancreatic cancer. Eventually the trial took place at the University of Maryland Medical Center in Baltimore, MD, and Hadassah, Sheba, Hillel Yafeh and Meir Medical Centers in Israel. The outcome of this project received FDA approval after the completion of the clinical trials
Read Less#1174